Clinical trials
Psoriasis trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
52 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 3 |
| 2003 | 1 |
| 2004 | 2 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 4 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 4 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 5 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 38 |
| Terminated | 5 |
| Active, not recruiting | 3 |
| Not yet recruiting | 2 |
| Recruiting | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pfizer | 5 |
| AbbVie | 4 |
| Radboud University Medical Center | 4 |
| Amgen | 3 |
| Boehringer Ingelheim | 3 |
| Stiefel, a GSK Company | 3 |
| Eli Lilly and Company | 2 |
| Janssen Research & Development, LLC | 2 |
| Janssen-Cilag International NV | 2 |
| Wyeth is now a wholly owned subsidiary of Pfizer | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Psoriasis | 52 |
| Arthritis, Psoriatic | 5 |
| Arthritis | 3 |
| Bronchiolitis Obliterans Syndrome | 3 |
| Dermatitis, Atopic | 3 |
| Lymphoma, Follicular | 3 |
| Plaque, Amyloid | 3 |
| Pruritus | 3 |
| Arthritis, Rheumatoid | 2 |
| Crohn Disease | 2 |
Trials
Showing 1 to 25 of 52. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.